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Streptokinase is an effective thrombolytic agent which, with early restoration of coronary blood flow, has 
the potential for limiting infarct size. Distinct from thrombolysis, we studied the effects of streptokinase on 
reperfusion coronary blood flow and infarct size. Open-chest anesthetized canines underwent a 90 minute 
snare occlusion of the left circumflex coronary artery followed by release and reperfusion through a critical 
stenosis for 6 hours. The animals were assigned randomly to two groups. Intracoronary streptokinase [group 
1 (n = 8): 6000 IU/ kg in 3 ml of saline] or saline [group 2 (n = 8): 3 ml of saline] was infused at 0.05 
ml/min for 60 minutes beginning 30 minutes before reperfusion. Coronary blood flow was stable in group 1 
during reperfusion, while in group 2 it fell during 6 hours of reperfusion (30 f 4 ml /min to 18 f 2 ml/min, 
P = 0.05). The ST-segment elevation on the limb lead II electrocardiogram 15 minutes after coronary artery 
occlusion was similar in both groups (group 1: 3.9 f 0.6 mV, group 2: 2.3 f 0.5 mV), suggesting the extent of 
myocardial ischemia was also similar in both groups. The infarct sizes were similar when expressed both as a 
percent of the total left ventricular mass [(IZ/LV) group 1: 17 f 2.5%, group 2: 17.5 f 2.5%] or as a percent 
of the area at risk of infarction [(IZ/AR) group 1: 39 f 6%, group 2: 39 f 5%]. In both groups, the mass of 
left ventricle dependent on the blood flow distribution of the left circumflex coronary artery was similar 
when compared to total left ventricular mass [(AR/LV) group 1: 41 f 3%, group 2: 44 f 4%]. These results 
demonstrate that streptokinase maintains reperfusion coronary blood flow through a critical stenosis at a 
rate similar to baseline levels. Despite the fact that coronary blood flow remained stable with streptokinase 
during reperfusion, infarct size was not limited after 90 minutes of fixed coronary artery occlusion in this 
canine model of myocardial injury. 
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intracoronary thrombus formation, frequently at 
or near a stenotic artherosclerotic lesion [1,2]. 
Although the subsequent extent of myocardial 
necrosis is dependent on collateral blood flow to 
the ischemic area, it is known that myocardial 
contractility in the ischemic area is markedly de- 
creased immediately after coronary artery occlu- 
sion [3], whereas irreversible damage progresses 
over several hours [4]. Attempts to restore coronary 
blood flow as early as possible are undertaken 
with the intent of decreasing functional myocar- 
dial damage and improving patient survival [5-81. 
Restoration of coronary blood flow can frequently 
be accomplished with early administration of 
thrombolytic agents such as streptokinase or tissue 
plasminogen activator. 
After reperfusion, high-grade stenosis may be 
present at the site of previous thrombosis. The 
residual lumen size can change significantly dur- 
ing the first two weeks after successful thrombo- 
lytic therapy as ruptured atherosclerotic plaques 
are remodeled, vasospasm resolves and persistent 
microthrombi are lysed endogenously. Coronary 
arteries with residual stenotic cross-sectional areas 
less than 0.4 mm2 are at high risk for rethrombosis 
[9]. The clinical problems embodied in rethrombo- 
sis include reinfarction with concomitant loss of 
functional myocardium and the increased risk of 
sudden death [lo]. 
Estimates of residual luminal area are used as 
an indicator of coronary blood flow in the clinical 
situation, because direct measurements are not 
available [ 111. In the present study, coronary blood 
flow was continuously monitored in an experi- 
mental animal model of coronary artery occlusion 
with reperfusion through a critical stenosis. The 
extent of myocardial injury was directly measured 
after 6 hours of reperfusion. Distinct from its 
thrombolytic activity, the effect of streptokinase 
on the pattern of reperfusion coronary blood flow 
and the extent of myocardial necrosis was de- 
termined. The results of this investigation indicate 
that streptokinase does maintain reperfusion 
coronary blood at a rate similar to baseline levels. 
Despite persistently stable coronary blood flow, 
the extent of myocardial infarction which resulted 
after a 90 minute coronary artery occlusion and 6 
hours of reperfusion was not limited by in- 
tracoronary streptokinase administration in this 
experimental model. 
Methods 
Occlusion-reperfusion myocardial injury 
Male mongrel canines (13-16 kg) were anesthe- 
tized with dial urethane intravenously (500 
mg/kg), endotracheally intubated and ventilated 
with room air at a tidal volume of 30 ml/kg and a 
frequency of 12 breaths/mm (Harvard respirator, 
Harvard Apparatus, S. Natick, MA). The left 
carotid artery and internal jugular vein were ex- 
posed and catheters were inserted for monitoring 
arterial pressure (Statham P23DC pressure trans- 
ducer, Gould Inc., Cardiovascular Products, 
Oxnard, CA) and infusing fluids, respectively. A 
left thoracotomy was performed in the fifth inter- 
costal space and the heart was suspended in a 
pericardial cradle. A catheter was advanced from 
the left atrium into the left ventricle for monitor- 
ing left ventricular pressure. 
A two cm section of the left circumflex coronary 
artery was isolated proximal to the first obtuse 
marginal branch and instrumented proximal to 
distal as follows: infusion cannula, electromag- 
netic flow probe (Model 501, Carolina Medical 
Electronics, Inc., Ring, NC), and critical stenosis. 
The small intervening coronary branches over the 
two cm segment were ligated (Fig. 1). A 26-gauge 
hypodermic needle tip was formed into a “u” and 
inserted into tygon tubing (0.03 cm, internal diam- 
eter) to be used as the intracoronary infusion 
cannula. The critical stenosis was produced by 
constricting the circumflex coronary artery with 
O-silk tied around the artery and an 18-gauge 
blunt needle. The needle was quickly removed, 
thus leaving a smaller residual arterial lumen. The 
mean resting coronary blood flow was not af- 
fected by the critical stenosis; however, a 50% 
decrease in hyperemic blood flow was produced. 
Angiographic evaluation of a critical stenosis 
which limited by 50% the hyperemic response to a 
10 set occlusion of the circumflex coronary artery 
was performed in a representative experimental 
preparation. Biplane digital coronary angiograms 
were obtained in projections that optimized sep- 
375 
Fig. 1. Instrumentation of the left circumflex (LCx) coronary artery. The proximal 2 cm of the artery were isolated 




aration of the circumflex stenosis from surround- 
ing vessels. Angiograms were acquired on a digital 
angiographic computer (DPS-4100C, ADAC 
Laboratories, Edenvale, CA) interfaced to a stan- 
dard cineangiographic system (Philips Optimus 
M200, Eindhoven, The Netherlands). The images 
were processed and analyzed with a previously 
described automatic coronary quantitation pro- 
gram [12]. 
Continuous recording of blood pressure, left 
ventricular pressure, left ventricular f dP/dt, limb 
lead II electrocardiogram, and mean and phasic 
left circumflex coronary artery blood flow were 
obtained on a polygraph recorder (Model 7, Grass 
Instrument Co., Quincy, MA). 
Protocol 
Thirty minutes after the surgical preparation 
was completed, the left circumflex coronary artery 
was occluded proximal to the critical stenosis but 
distal to the infusion cannula by compression with 
soft teflon tubing and a snare for 90 minutes. 
Either intracoronary streptokinase [group 1 (n = 
8): 6000 IU/kg in 3 ml of 0.9% saline] or saline 
[group 2 (n = 8): 3 ml of 0.9% saline] was infused 
at a rate of 0.05 ml/mm for 60 min, beginning 
during the last 30 min of occlusion and continuing 
the first 30 min of reperfusion. Reperfusion was 
accomplished by slowly loosening the snare over a 
30 minute period and then observation was con- 
tinued for a total of 6 hours. The heart was 
and instrumented 
fibrillated electrically and removed quickly for 
postmortem quantification of infarct size. 
Only canines which had electrocardiographic 
evidence of ischemia (ST-segment elevation) and 
then survived 6 hours of reperfusion were included 
in the data analysis. Four canines fibrillated dur- 
ing coronary artery occlusion and only one was 
successfully resuscitated ( < 3 defibrillation at- 
tempts). One canine fibrillated upon reperfusion, 
during a streptokinase infusion, and it was suc- 
cessfully resuscitated. Four animals were excluded 
because left circumflex coronary artery blood flow 
fell outside the range established for the cohort 
(15-40 ml/mm). Two other animals were ex- 
cluded because they had a significant fall in mean 
arterial blood pressure (MAP 5 80 mm Hg) at the 
time of coronary artery occlusion, prior to rando- 
mization into either group, which was probably 
secondary to dehydration. The number of canines 
successfully studied in each of the two groups was 
eight. 
Postmortem quantification of infarct size 
Myocardial infarct size was quantified using an 
in vitro dual perfusion method described previ- 
ously [13]. Cannulas were inserted into the cir- 
cumflex coronary artery at the site of the stenosis 
and into the aorta above the coronary ostia. The 
circumflex bed was perfused with 1.5% triphenyl- 
tetrazolium hydrochloride in 20 mM potassium 
phosphate buffer (pH 7.4, 38” C). The coronary 
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ostia were perfused via the aorta retrogradely with 
0.25% Evans blue stain. Both the circumflex re- 
gion and the remainder of the heart were perfused 
with their respective stains at a constant pressure 
of 100 mm Hg for 5 min at 37 o C. The heart was 
cut into six equal sections, 1.0 cm thick, per- 
pendicular to the apex-base axis. The area of the 
left ventricle at risk for infarction due to it 
anatomic dependence on the circumflex coronary 
artery for blood flow was identified by the lack of 
Evans blue staining. The region of infarcted 
myocardium within the area at risk was de- 
marcated by the lack of staining with triphenylte- 
trazolium hydrochloride [14,15]. Transverse 
ventricular sections were traced onto clear plastic 
overlays. Planimetry was used to determine the 
total left ventricular area, the area at risk and the 
area of infarction. Ventricular sections were trim- 
med of right ventricular, valvular, and fatty tissue 
and weighed. Infarct size was expressed as percent 
of the anatomic area at risk and the total left 
ventricle. In a previous study. gravimetric analysis 
agreed closely with determinations of infarct size 
obtained from planimetry of the overlay tracings 
U61. 
Platelet and coagulation studies 
In a second group of male mongrel canines, 
blood (20 ml) was withdrawn from the internal 
jugular cannula into a plastic syringe containing 
3.2% sodium citrate as the anticoagulant [l : 10 
citrate/blood (vol : vol)] at baseline, 15 minutes of 
reperfusion, and 6 hours of reperfusion after treat- 
ment with intracoronary streptokinase (6000 
IU/kg over 1 hour). The platelet count was de- 
termined with a Haema Count MK-4/HC system. 
Platelet rich plasma (PRP), the supernate present 
after centrifuging anticoagulated whole blood at 
1000 rpm for 5 minutes (140 x g), was diluted 
with platelet poor plasma (PPP) to achieve a 
platelet count of 200,000/mm3. PPP was prepared 
after the PRP was removed by centrifuging the 
remaining blood at 12,000 x g for 10 minutes and 
discarding the bottom cellular layer. Ex vivo 
platelet aggregation was measured by established 
spectrophotometric methods using a four channel 
aggregometer (BioData-PAP-4) by recording the 
increase in light transmission through a stirred 
suspension of PRP maintained at 37 o C [17]. Ag- 
gregation was induced with collagen (1 : 10 and 
1 : 80 dilution of Ethicon Collagen Dispersion-TD 
150) and archidonic acid [0.65 mM and 0.325 mM 
(AA)]. Epinephrine (550 nM) was used to prime 
the platelets prior to AA stimulation. Values were 
expressed as percentages of light transmission 
standardized to PRP and PPP samples yielding 0% 
and 100% light transmission, respectively. 
At similar time points, fibrinogen levels and 
fibrin/ogen split products (FSP) were measured. 
Fibrinogen was determined with thrombin reagent 
[lyophilized bovine thrombin. 100 NIH units/ml 
(Becton. Dickinson and Co., Rutherford, NJ 
07070)] and Owren’s Verona1 buffer (0.0284 M 
sodium barbital in 0.125 M NaCl, pH 7.35). The 
clotting time obtained was compared with that of 
a standardized fibrinogen preparation. Control 
plasma for this assays was a lyophilized prepara- 
tion of human plasma [Ci-Trol Coagulation Con- 
trol, Level I (American Dade, Aguada, Puerto 
Rico 00602)]. Sample tubes for FSP assays con- 
tained thrombin (20 NIH units) and soy bean 
trypsin inhibitor [approx 3600 NF units (Well- 
come Laboratories, Beckenham, UK)]. The FSP 
were detected with immunological methods ob- 
serving the agglutination or clumping of Latex 
Anti-Fibrinogen [0.6% suspension of polystyrene 
latex particles coated with rabbit anti-human 
fibrinogen in buffer (American Dade. Aguada. 
Puerto Rico 00602)] and Sorensen’s buffer (0.1 M 
glycine and 0.1 M saline, pH 8.2). 
Statistical analysis 
Data were expressed as mean + SEM. Dif- 
ferences between the two groups were determined 
by Student’s t-test, and were considered signifi- 
cant if P < 0.05. When appropriate in the analysis 
of measured parameters, differences within and 
between groups over time were determined by 
repeated measures analysis of variance using New- 
man-Keul’s multiple range test to detect where 
differences were located among the subpopulation 





Sixteen canines were successfully studied in this 
occlusion-reperfusion model of myocardial injury 
[streptokinase (group 1, n = S), saline (group 2, 
n = 8)]. There was no difference in the weights of 
canines between the two groups [group 1: 15.0 + 
1.4 kg, group 2: 15.0 + 0.9 kg (mean + SEM)], nor 
in the weights of the hearts (group 1: 135 _t 7 g, 
group 2: 129 +_ 8 g). There were no significant 
differences in recorded parameters (heart rate, left 
ventricular pressure, blood pressure, left cir- 
cumflex coronary artery blood flow) determined 
between the groups at the beginning of the experi- 
ments. 
Critical stenosis quantitative arteriography 
The orthogonal image that showed the stenosis 
optimally was processed both with and without 
mask subtraction. After subtraction. the visual 
percent stenosis determined with calipers was 60% 
in the proximal left circumflex coronary artery 
(Fig. 2a). Subtracted and nonsubtracted digital 
a 
Fig. 2. Quantitative arteriography of circumflex coronary artery stenosis. The image showing the stenosis optimally was processed 
both with and without mask subtraction. (a) After subtraction, there was a 60% stenosis determined visually with calipers (arrow). (b) 
Digital images underwent gray-scale inversion producing white-on-black pictures with a four-fold magnification. (c) The final 
computer output consisted of the arterial image with arterial edges, centerline, and plots of geometric diameter, densitometric relative 
cross-sectional area, and maximal diameter stenosis. The arterial diameter at the critical stenosis was 1.46 mm. From this 
information, a 56.5% diameter stenosis and an 81% cross-sectional area stenosis were calculated. 




Hemodynamic profiles in control and streptokinase-treatment groups. 
MAP * Heart rate RPP * 
CT SK CT SK CT SK 
Baseline 118k 6 111* 5 134 + 7 143 f 5 181 + 16 178 + 13 
15 min occ 11Ok 6 95+ 6 141 k 6 135 * 5 173 f 12 155 f 10 
15 min rep 108k 4 97* 5 134& 6 132 f 7 155 i 19 162 + 12 
1 hr rep 109+ 6 965 4 135 f 7 133 * 6 173 * 19 156f 6 
2 hr rep 111 f 11 92 f 12 141* 7 136 f 7 179 + 15 164* 5 
3 hr rep 107+ 7 97 * 13 141* 4 136+7 189 * 11 171i 9 
4 hr rep llO+ 8 92* 12 149 * 5 138f8 201 + 12 170f 8 
5 hr rep 104* 7 95 + 14 154 f 2 144_t6 203 f 12 184 f 12 
6 hr rep 102* 5 97 f 12 156*3 ** 140f6 196 + 16 180 f 13 
Data are expressed as mean i SEM: CT = control (n = 8): SK = streptokinase (n = 8); MAP = mean arterial pressure (mm Hg): 
RPR = rate pressure product (mm Hg/min X 100); heart rate = beats/min; occ = occlusion; rep = reperfusion. 
* No significant difference between groups at the same time point but significant change over time (MAP P = 0.02, RPP P < 0.05). 
Control heart rate increased over time and compared to streptokinase at 6 hour rep ( * * P = 0.02). 
images underwent gray-scale inversion to pro- 
duced white-on-black pictures with a four-fold 
magnification (Fig. 2b). The final computer out- 
put consisted of the arterial image with arterial 
edges, centerline, and plots of geometric diameter, 
densitometric relative cross-sectional area, and 
maximal diameter stenosis (Fig. 2~). The arterial 
diameter at the critical stenosis was 1.46 mm. 
From this information, a 56.5% diameter stenosis 
and an 81% cross-sectional area stenosis were 
calculated. 
Hemodynamic responses 
There was no difference in mean arterial blood 
pressure recorded between the two groups over the 
course of the experiment. In both groups, the 
animals experienced a moderate fall in mean 
arterial blood pressure 15 min after left circumflex 
coronary artery occlusion which persisted 
throughout reperfusion (Table 1). The initial de- 
crease in mean arterial pressure was more promi- 
nent in group 1 than the change which occurred in 
group 2, however this difference was not signifi- 
cant. The fall in mean arterial pressure induced by 
coronary artery occlusion occurred before strep- 
tokinase had been infused. After 6 hours of reper- 
fusion, the heart rate of canines in group 2 had 
increased significantly over time, from 134 k 7 
bpm to 156 + 3 bpm (P = 0.02). This final heart 
rate in group 2 was higher than that observed in 
group 1 (P = 0.02). Despite these hemodynamic 
changes, there was no point in time when the rate 
pressure product was different between groups. 
However, overtime within groups there was a sig- 
nificant change in the rate pressure product (P -c 
0.05). 
Circumflex coronary artery blood flow patterns 
The baseline circumflex coronary blood flow in 
groups 1 and 2 were not significantly different 
TABLE 2 
Left circumflex coronary artery blood flow in control and 
streptokinase-treatment groups. 
Blood flow (ml/min) 
SK CT 
Baseline 20*2 26k3 
15 min rep 24k3 30+4 
1 hr rep 19+3 25i5 
2 hr rep 17*3 21*4 
3 hr rep 18*3 2Ok4 
4 hr rep 15*3 2Oi4 
5 hr rep 16*3 19*4 
6 hr rep 16*2 18*2 * 
Data are expressed as mean+ SEM: CT = control (n = 8): 
SK = streptokinase (n = 8); rep = reperfusion. No significant 
difference between groups at the same time point but signifi- 
cant change over time in control group ( * P < 0.05). 
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(20 k 2 ml/min vs 26 f 3 ml/min, respectively, 
Table 2). During the 6 hour reperfusion period, 
blood flow in group 1 was stable and did not 
decrease significantly (24 &- 3 ml/min to 16 + 2 
ml/min). In contrast, the coronary blood flow in 
group 2 slowly decreased over the 6 hour reperfu- 
sion period, from 30 k 4 ml/min to 18 + 2 ml/min 
(P = 0.05). There were no oscillations or sponta- 
neous hyperemias detected in coronary blood flow 
during the reperfusion period in either group. 
Effect of occlusion-reperfusion on myocardial 
&hernia and infarct size 
The ST-segment elevation on the limb lead II 
electrocardiogram 15 minutes after coronary artery 
occlusion was similar in both groups (group 1: 
3.9 + 0.6 mV, group 2: 2.3 _t 0.5 mV), suggesting 
the extent of myocardial ischemia was also similar 
in both groups. During the course of the protocol 
ST-segment elevation tended to resolve and was 
replaced by Q waves and T wave inversion in all 
cases, and this then corresponds with evolution of 
a transmural myocardial infarction. The areas of 
the left ventricle at risk for infarction (AR/LV) 
were similar in the two groups (Fig. 3), demon- 
strating that the anatomic dependence on the 
proximal circumflex artery was similar. The region 
of infarcted myocardium within the area at risk 
(IZ/AR) and the total left ventricle (IZ/LV) were 
similar for the two groups. The weight of the left 
ventricle (group 1: 85 + 6 g, group 2: 75 _+ 4 g) 
and of the infarcted mass of tissue were similar in 
the two groups (group 1: 14 i 3 g, group 2: 13 + 3 
TABLE 3 
IZIAR lZ/LV ARILV 
n group 1 (n=8) streptokinase i.c. 
0 group 2 (n=8) control saline 
Fig. 3. Myocardial infarct size. Quantitation of infarct size is 
expressed with respect to infarct zone (IZ) as a percent of the 
area at risk (AR) and as a percent of the total left ventricle 
(LV). There was no difference in infarct size between group 1 
(streptokinase) and group 2 (saline). nor was there a difference 
in the area of left ventricle at risk for infarction (AR/LV). 
g). These infarct sizes were determined after a 
fixed time of occlusion (90 minutes) and a fixed 
time of reperfusion (6 hours), and these timing 
intervals should have been adequate for determin- 
ing the full extent of myocardial injury. Thus 
when streptokinase was used as an adjunct during 
occlusion-reperfusion myocardial injury, infarct 
size was not limited in this experimental model. 
Platelet and coagulation studies 
The platelet counts tended to fall over the 
course of the study but this decrease did not reach 
a significant level (Table 3). The platelet aggrega- 
tion studies were similar at baseline, 15 minute 
reperfusion, and 6 hour reperfusion for both 
agonists (collagen and arachidonic acid). It seems 
Platelet and coagulation studies in canines treated with intracoronary streptokinase. 
Platelet count Aggregation studies * Fibrinogen 
( x10’/mm3) Collagen Arachidonic acid (mM) (mg/dl) 
1: 10 1 : 80 0.325 0.650 
Baseline 332 + 46 78 f 9 44i 10 83 i 7 83 + 6 385 f 30 
15 min rep 281 * 41 74 i 8 64+ 9 80 * I 76 f 7 352 + 27 
6 hr rep 285 * 31 71 i 9 33 f 12 72 i 9 74 + 8 355 * 33 
Data are expressed as mean * SEM (n = 13): rep = reperfusion; FSP = fibrinogen split products. 
* Platelet aggregation reported as % light transmittance or % aggregation. 




153 * 21 * * 
214 * 42 * * 
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that the streptokinase had no demonstrable effect 
on ex vivo platelet reactivity. At the beginning of 
each experiment, coagulation studies including, 
fibrinogen levels and fibrin/ogen split products 
(FSP), were performed. The fibrinogen level fell 
slightly after the intracoronary streptokinase infu- 
sion and remained at this level after 6 hours of 
reperfusion (P = NS). The FSP were consistently 
elevated after initiation of the streptokinase infu- 
sion and remained so for the 6 hours duration of 
the protocol (P < 0.001). 
Discussion 
The intravenous infusion of streptokinase is 
effective in reestablishing coronary blood flow 
during acute myocardial infarction. Although re- 
occlusion related reinfarctions and deaths occur 
after thrombolytic therapy, there are clinical trials 
in which long-term survival improved in those 
patients treated with streptokinase [l&20]. The 
reported reinfarction rates are determined by in- 
tention to treat, often without establishing effec- 
tive thrombolysis, and may be underestimated. 
However, the reinfarction rates appear to be simi- 
lar for streptokinase and tissue plasminogen 
activator [21]. Those vessels with more severe 
residual stenosis comprise one anatomic subgroup 
at risk for rethrombosis, both with streptokinase 
and tissue plasminogen activator [9,22]. 
There are animal models which have been 
developed to study thrombotic coronary artery 
occlusion [23,24]. Electrical induction of thrombo- 
sis has been employed to define several clinical 
interventions [25]: anti-thrombotic agents, throm- 
bolytic agents and prevention of rethrombosis. 
Recent interest has focussed on the latter two 
points. The electrically induced thrombus closely 
resembles the clinical situation with respect to clot 
composition, presence of a critical stenosis and an 
intimal lesion. In this model, if the thrombolytic 
agent is effective, mean coronary blood flow dur- 
ing reperfusion is significantly lower than baseline 
flow [26,27]. Inspite of this reduction in coronary 
blood flow, infarct size is smaller after thrombo- 
sis- thrombolysis myocardial injury than occlu- 
sion-reperfusion myocardial injury.. When the data 
from our previous study [28] were compared to the 
data from the study presented herein, those in- 
farcts produced in the thrombosis-thrombolysis 
model were smaller (IZ/AR P -c 0.005, IZ/LV 
P < 0.005), while the area at risk for infarction 
(AR/LV) was similar. There are several possible 
reasons for the descrepancies. Initial coronary 
artery occlusion time is somewhat unpredictable 
in thrombosis-thrombolysis studies when com- 
pared to performing a snare occlusion for a fixed 
period. Furthermore, in most studies evaluating 
thrombolytic efficacy of an agent, reocclusion is 
not reported or heparin is used with the thrombo- 
lytic agent to prevent reocclusion, so assessing 
infarct size or the incidence of rethrombosis is 
dependent upon more than one variable [29,30]. 
There has been some suggestion that streptokinase 
may limit infarct size by mechanisms in addition 
to thrombolysis, i.e. scavenging oxygen-derived 
free radicals or a decrease in vascular resistance of 
the coronary circulation within the ischemic zone. 
Although streptokinase is adequate for induc- 
ing thrombolysis acutely in the electrical induction 
model of coronary artery thrombosis, alone it does 
not alter the thrombogenic nature of this insult 
enough for the vessel to remain patent after the 
infusion is stopped [26]. Initial reperfusion 
coronary blood flow is lower than preocclusion 
flow and often has an unstable pattern which 
terminates in rethrombosis after several hours. 
This oscillating coronary blood flow pattern does 
not occur in the occlusion-reperfusion model used 
in this study; however, the occlusion-reperfusion 
model is compromised by diminished reperfusion 
coronary blood flow which can be improved upon 
with streptokinase. Oscillations and/or the de- 
creased blood flow patterns seen in these two 
models may represent a spectrum of the same 
problem: persistent platelet aggregation, intermit- 
tent distal no-reflow due to leukocyte plugging, or 
vasospasm. The histology of experimentally evoked 
thrombi [24,31], as well as those found in coronary 
arteries at necropsy of patient with acute myocar- 
dial infarction, further support an important role 
for platelets [32]. In this study, streptokinase did 
not alter ex vivo platelet reactivity; however, no 
attempt was made to determine if there were 
platelet aggregates within the ischemic zone. 
382 
The role of leukocytes in occlusion-reperfusion 
injury involves both the myocardium, i.e. infarct 
size [33], and the coronary microcirculation [34]. 
The possibility that diminished reperfusion blood 
flow in the infarct vessel is due to distal no-reflow 
and leukocyte plugging has been studied using 
prostaglandin E, (PGE,) in the occlusion-reper- 
fusion model [35]. Neutrophil migration into in- 
flammatory areas, production of superoxide anion 
in vitro, and infarct size were all decreased with 
PGE,, while reperfusion blood flow improved 
compared to control animals. Although reperfu- 
sion coronary blood flow was not continuously 
monitored by Chatelain et al. [36], after 3 hour 
occlusion and 30 minute reperfusion, a hyperemic 
response in coronary blood flow was evident in 
neutropenic, but not control animals. Interstitial 
and microvascular leukocyte accumulation were 
found in the controls but not in the neutropenic 
animals, thus the presence of neutrophils may 
effect reperfusion coronary blood flow. Forman et 
al. [37] found regional myocardial blood flow di- 
minished after 90 minute occlusion and 1 hour 
reperfusion; however, the vasodilatory reserve was 
preserved when an antineutrophil agent, perfluo- 
rochemical, was infused during reperfusion. Light 
and electron microscopy of the ischemic region 
revealed capillary obstruction by endothelial cell 
protrusions and neutrophils in control animals not 
the perfluorochemical-treated animals. In the pre- 
sent study, we did not assess neutrophil accumula- 
tion within the ischemic zone. 
Neutrophils have also been implicated in 
myocardial dysfunction which occurs after brief 
periods of coronary artery occlusion and reperfu- 
sion [38]. Aside from physically obstructing flow 
in the capillary bed, neutrophils release sub- 
stances, i.e. superoxide radical, arachidonic acid 
metabolites and enzymes, which effect coronary 
vascular tone and contribute to myocardial dys- 
function and injury. Products of the S-lipo- 
xygenase pathway of arachidonic acid metabo- 
lism, leukotrienes, have been shown to induce 
diffuse peripheral constriction in the coronary 
arteries [39]. In a previous study, we found that 
streptokinase did not alter in vitro neutrophil free 
oxygen radical production, not did it act as a 
hydroxyl or superoxide radical scavenging agent 
[40]. In vitro studies may not predict in vivo 
effects of streptokinase on platelets, neutrophils, 
and the vasoactive substances released. However, 
it appears that these factors are important and 
may need to be eliminated or modified in order to 
establish adequate stable reperfusion coronary 
blood flow. 
Reperfusion coronary blood flow, myocardial 
function, and infarct size are clinically relevant 
issues. In acute anterior myocardial infarction, 
after either thrombolysis or angioplasty, a high 
grade residual stenosis or a prolonged period of 
ischemia prior to reperfusion limit the increase in 
estimated coronary blood flow upon reperfusion. 
Functional recovery at 10 days directly correlated 
with acute increases in coronary blood flow [41]. 
Early establishment of adequate myocardial perfu- 
sion, not just the restoration of coronary blood 
flow, should be used as a guideline to assure the 
success of interventions designed to limit infarct 
size. The findings of this animal study using an 
occlusion-reperfusion model of myocardial injury, 
suggest that streptokinase can increase reperfusion 
coronary blood flow. Although coronary blood 
flow upon reperfusion was similar to baseline 
levels, infarct size was not limited in this animal 
model. 
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